Background
Epidemiologic evidence shows that folate deficiency is a breast cancer risk factor [
1,
2]. MTHFR is a key enzyme in the folate metabolism pathway and regulates the intracellular folate pool for synthesis and methylation of DNA [
3,
4]. Two common allele variants of the
MTHFR gene have been described, C677T (NCBI SNP ID: rs1801133) and A1298C (rs1801131), that lead to amino acid substitutions, Ala222Val and Glu429Ala, and to decreased enzyme activity [
5‐
7]. Heterozygous and homozygous carriers of the 677T allele variant have a 30–40% and 60–70% reduced enzyme activity, respectively, as determined by
in vitro analysis of the MTHFR activity [
5,
7,
8]. The effect of the 1298C allele variant is less severe and homozygous carriers of this allele have a more moderate 30–40% reduction of the enzyme activity, yet its function remains controversial [
6,
7,
9]. Furthermore, people who are heterozygous at both loci, C677T and A1298C, experience an intermediate activity loss of 40–50% [
6,
7]. It has been shown that the 677T variant increases the plasma homocysteine concentration in humans and reduces DNA methylation in cancer patients, which indicates a reduced synthesis of methionine and a more limited availability of the methyl donor, S-adenosyl-methionine, in the presence of the low activity T allele [
5,
10]. Many studies investigated the association between the two genotypes and breast cancer incidence. Although significant associations were observed in some studies, a clear linkage between
MTHFR gene polymorphisms and the risk to develop breast cancer has not been established [
11‐
18].
Recently, the two
MTHFR genotypes were found to modulate the chemosensitivity of cancer cells to 5-fluorouracil and methotrexate [
8,
19]. Furthermore, the 677T variant has been linked to severe toxicity during adjuvant treatment of breast cancer with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) [
20]. Other reports observed differing effects of the two genotypes on methotrexate efficacy and toxicity in patients with rheumatoid arthritis [
21‐
23]. We hypothesized that the two SNPs may affect outcome of breast cancer patients with surgery and chemotherapy and studied the individual and combined effects of the SNPs on breast cancer survival. Because the tumor estrogen receptor-α (ER) status, race/ethnicity, and alcohol consumption have been shown to influence the metabolism of folate [
1,
2,
17,
24‐
28], we also examined possible interactions between these factors and the two
MTHFR SNPs on breast cancer survival.
Discussion
In our study of 248 African-American and Caucasian women with incident breast cancer, the MTHFR gene polymorphisms, C677T and A1298C, were associated with breast cancer survival. The effects were stronger in patients with estrogen receptor-negative tumors. We also observed an interaction between the two SNPs and race/ethnicity on breast cancer survival. The interaction decreased the survival hazard among African-American women and increased the survival hazard among Caucasian women. This finding indicates that race/ethnicity is an important modifier of the effect that MTHFR genotypes have on breast cancer survival.
It is plausible that
MTHFR gene polymorphisms influence breast cancer survival. Folate is critical for DNA synthesis, DNA repair and epigenetic regulation of transcription. Folate deficiency causes uracil misincorporation into human DNA and induces chromosome breakage, and it has been argued that the protective effect of the 677T allele in colon cancer is related to a decreased incorporation of uracil into DNA [
33,
34]. There is evidence that the 677T allele increases thymidylate synthase activity in cancer cells because of an increased supply of 5,10-methyleneTHF, the methyl donor for methylation of dUMP to dTMP [
8]. This increase of dTMP synthesis may come at the cost of a diminished global DNA methylation because cancer patients with a 677T allele (C/T or T/T) have constitutively low levels of 5-methylcytosine in their tumors and surrounding normal tissue [
10]. Animal experiments support the notion that a low MTHFR activity leads to decreased DNA methylation. Heterozygous and homozygous
MTHFR knockout mice have significantly lower S-adenosylmethione levels and global hypomethylation when compared to the
MTHFR wild-type littermates [
35]. Distinct DNA hypermethylation profiles have been associated with breast cancer and may lead to disease progression and metastasis [
36]. However,
MTHFR gene polymorphisms also affect the efficacy and toxicity of chemotherapeutics [
37]. Because the direction of the effect is not uniform [
19,
20,
38], and because intrinsic factors and lifestyle may further modify the effect of
MTHFR gene polymorphisms, it is difficult to predict how
MTHFR gene polymorphisms will influence cancer outcome.
There has been only one other study that examined the effect of
MTHFR genotypes on breast cancer survival, and the authors did not observe a significant association between the two SNPs and survival of breast cancer patients from the Shanghai area in China [
39]. Differences between these results and our associations could be due to examining different populations. Our study provided evidence that the effect of
MTHFR genotypes on breast cancer survival differs by race/ethnicity. It is likely that the prevalence of factors that may influence the effect of
MTHFR genotypes on breast cancer survival, such as tumor ER status, mode of therapy, or folate status, is different from patient population to patient population. For example, ER-negative tumors are more common among African-American women than other race/ethnic groups and these tumors are treated differently than ER-positive tumors [
40]. Most patients in the Shanghai Breast Cancer study appear to have received 5-fluorouracil, a therapy that was infrequent in our patient group. Race/ethnicity is also a determinant of the folate status. African-Americans tend to have a lower folate intake than other race/ethnic groups and in a controlled trial, blood folate concentrations and folate excretion varied by race/ethnicity although the dietary folate intake and the C677T genotype were the same among all participants [
26,
27]. This observation that the folate status is different by race/ethnicity in a population matched on the C677T genotype (all C/C) and with identical folate intake may explain why we observed an interaction between race/ethnicity and the
MTHFR genotypes on breast cancer survival. Finally, it should be mentioned that an ER-negative tumor status was a significant independent predictor of poor outcome in our population but it was not in the Shanghai Breast Cancer Study as judged by the 5-year survival rate [
39].
The finding that
MTHFR genotypes are associated with breast cancer survival depending on the tumor ER status is novel. It has been observed that total folate intake is associated with the incidence of breast cancer depending on the tumor ER status. In the Nurses' Heath Study, a higher folate intake was associated with a lower risk of ER-negative but not ER-positive breast cancer [
17]. The authors hypothesized that adequate folate intake may be primarily important in preventing ER-negative tumors. ER-negative tumors may represent a distinct subtype of breast cancer, as revealed by the gene expression patterns of human breast tumors [
41,
42], and MTHFR may have a more significant role in the development and progression of this tumor type than ER-positive tumors. It is also possible that the estrogen receptor regulates the intracellular folate metabolism, a function, which would be lost in ER-negative tumors. There is support for this hypothesis. The estrogen receptor has been shown to repress the expression of the folate receptor α, and an inverse correlation between ER and folate receptor expression in breast cancer has been reported [
24,
25]. The folate receptor α is overexpressed in many human malignancies and shuttles folate, folate conjugates, and antifolate compounds into cells [
43].
We found an opposite effect by C677T and A1298C on breast cancer survival although both variant alleles were found to decrease MTHFR enzyme activity [
5‐
7]. The 677T variant allele increased survival among ER-negative patients. The 1298C variant allele was associated with a significantly decreased survival of ER-negative patients. There is evidence that the two SNPs may have different effects on the biochemical properties of MTHFR [
9]. The A1298C leads to a substitution of a glutamine by alanine in the regulatory domain of the enzyme but does not cause thermolability of the enzyme or enzyme instability in the presence of low folate, like C677T [
7,
9]. Several reports showed that the two SNPs have different effects on the efficacy and toxicity of methotrexate and 5-fluorouracil. The 1298C variant allele was found to be associated with fewer adverse effects and higher efficacy and the 677T variant allele with an increased systemic toxicity in rheumatoid arthritis and cancer patients [
20,
21,
23,
38]. A methotrexate/5-fluorouracil-based therapy, however, was not a factor in our study. Most of the chemotherapy-treated patients received a combination of adriamycin and cyclophosphamide and only a few patients were treated with methotrexate and/or 5-fluorouracil.
Other studies observed opposite effects by these two SNPs. In the Long Island Breast Cancer Study, the 677T variant allele was associated with an increased risk of breast cancer and the 1298C variant allele was associated with a decreased risk of breast cancer [
15]. The authors hypothesized that the inverse correlations were caused by the linkage disequilibrium between C677T and A1298C that links a low activity genotype at one locus to a high activity genotype at the other locus [
31,
32]. Even though we observed a linkage between the two SNPs in our study population, it does not fully explain the opposite effects of the two SNPs on survival. We performed additional analyses where we controlled for the confounding effect of the second
MTHFR genotype. When we used this stratified approach, the two SNPs still had the same opposite effect on breast cancer survival. We further addressed the relationship between survival and
MTHFR genotypes by categorizing patients into carriers of diplotypes that encode a MTHFR enzyme with either a low or high activity, as estimated
in vitro [
6]. In this analysis, which examines the effect of MTHFR activity rather than genotypes, the risk estimates for breast cancer survival were remarkably similar for the low activity diplotype and the low activity 677T variant but different from 1298C suggesting that the effect of C677T on survival mirrors the enzyme activity loss while the effect of A1298C does not.
Our study has several limitations. The current sample size did not allow us a more in-depth examination of the effect of race/ethnicity in a stratified analysis and we performed a number of subgroup analyses, which increases the possibility of chance finding. The subgroup analyses addressed hypotheses based on previous findings from observational studies suggesting that the ER-status, race/ethnicity, and chemotherapy could act as effect modifiers of the
MTHFR genotypes. These hypotheses were formulated
a priori, and our data that the ER-status and race/ethnicity modify the effect of
MTHFR genotypes on survival are consistent with previous observations and biologically plausible. It is also a limitation that we could not include the patients' folate status into our analysis. Blood folate concentrations or a long-term assessment of the folate intake were not available. Folate intake is associated with the incidence of breast cancer and interactions between folate and
MTHFR genotypes in relation to breast cancer risk have been observed in several epidemiological studies [
2,
14,
15,
17]. Alcohol acts as a folate antagonist and is a modifier of the risk association between folate and breast cancer [
2,
17,
28]. We observed a significant interaction between A1298C and alcohol consumption on breast cancer survival. This observation may suggest that the folate status is a modifier of relationship between
MTHFR genotypes and breast cancer survival. There is one report that examined the relationship between folate intake and survival of breast cancer patients with chemotherapy [
44]. In the study, the authors did not observe a significant association between folate intake and breast cancer survival but the study did not examine
MTHFR genotypes.
Acknowledgements
This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. The authors thank Neil Caporaso (National Cancer Institute, Bethesda, MD) and Christopher Loffredo (Georgetown University, Washington, DC) for their help with the study design. We would also like to thank Raymond Jones, Audrey Salabes, Leoni Leondaridis, Glennwood Trivers, and personnel at the University of Maryland and the Baltimore Veterans Administration, and the Surgery and Pathology Departments at the University of Maryland Medical Center, Baltimore Veterans Affairs Medical Center, Union Memorial Hospital, Mercy Medical Center, and Sinai Hospital for their contributions. Damali N. Martin is a recipient of a NCI Cancer Prevention Fellowship.
Competing interests
The author(s) declare that they have no competing interests.
Authors' contributions
DNM and SA drafted the manuscript. DNM, BJB, and SA contributed to the design of the study. TMH, BJB, and SC contributed to data collection, DNA isolation, and genotyping. JEG, DNM, and SA performed statistical analyses. LEM and SC contributed to data analysis and interpretation. All authors read and approved the final manuscript.